New Product: Mayzent (siponimod fumaric acid) 0.25 mg and 2mg film-coated tablets

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
23 January 2020

Abstract

Siponimod fumaric acid is licensed for treatment of adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.